Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

15:06
10/09/16
10/09
15:06
10/09/16
15:06

Bristol-Myers reports CheckMate-275 data on Opdivo in urothelial cancer

Bristol-Myers Squibb announced results from the CheckMate -275 trial, in which Opdivo had a confirmed objective response rate, the primary endpoint, of 19.6% in platinum-refractory patients with metastatic urothelial carcinoma. Responses were observed in both PD-L1 expressors and non-expressors. The confirmed ORR in patients expressing PD-L1 greater than or equal to 1% was 23.8%, and 16.1% in patients expressing PD-L1 less than 1%. In patients expressing PD-L1 greater than or equal to 5%, the confirmed ORR was 28.4%, and 15.8% in patients expressing PD-L1 less than 5%. The median duration of response was not reached in the overall population with a minimum follow-up of six months, and responses were ongoing in 77% of patients. Among the 52 patients who responded to treatment, the median time to a response was 1.9 months. The median PFS was 2.0 months in all treated patients, 1.87 months for patients with PD-L1 less than 1%, and 3.55 months in patients with PD-L1 greater than or equal to 1%. The median OS was 8.74 months in all treated patients, 5.95 months in patients with PD-L1 less than 1%, and 11.3 months in patients with PD-L1 expression greater than or equal to 1%. The safety profile of Opdivo in this study was consistent with the safety profile of Opdivo in other tumor types. Overall, 4.8% of patients discontinued therapy due to treatment-related AEs of any grade, and 3.0% discontinued therapy due to grade 3-4 treatment-related AEs. The data will be presented at the 2016 European Society for Medical Oncology Congress.

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

VDNRF

Vedanta Resources

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Downgrade
Vedanta Resources rating change  »

Vedanta Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$134.14

2.16 (1.64%)

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Options
Notable pre-earnings option play in Expedia »

Notable pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

10:40
04/25/17
04/25
10:40
04/25/17
10:40
General news
Treasury Option Action: a round of positioning »

Treasury Option Action: a…

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:39
04/25/17
04/25
10:39
04/25/17
10:39
Hot Stocks
JetBlue says fleet review 'going to take a little bit of time' »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

, SSNLF

Samsung

10:38
04/25/17
04/25
10:38
04/25/17
10:38
Periodicals
Samsung to give new MRAM memory details next month, Patently Apple says »

Following on a report…

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

SSNLF

Samsung

IBM

IBM

$161.45

0.7 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

AVXS

AveXis

$79.18

2.42 (3.15%)

10:37
04/25/17
04/25
10:37
04/25/17
10:37
Hot Stocks
AveXis says AVXS-101 appears to have favorable safety profile in Phase 1 trial »

AveXis presented results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TSLA

Tesla

$308.03

2.43 (0.80%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Periodicals
Union workers claim Tesla illegally intimidated them, BuzzFeed says »

The United Automobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

AEP

American Electric

$67.86

-0.11 (-0.16%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Hot Stocks
American Electric says to invest $17.3B in capital over next three years »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

10:35
04/25/17
04/25
10:35
04/25/17
10:35
General news
U.S. consumer confidence fell to a still-robust 120.3 »

U.S. consumer confidence…

FCX

Freeport McMoRan

$13.19

0.955 (7.81%)

10:34
04/25/17
04/25
10:34
04/25/17
10:34
Hot Stocks
Freeport McMoRan says near-term debt situation ins manageable »

At some point looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Hot Stocks
JetBlue says early A321NEOs have Pratt & Whitney GTF engines »

JetBlue says "We…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

UTX

United Technologies

$117.06

0.74 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

BIIB

Biogen

$276.86

3.92 (1.44%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Recommendations
Biogen analyst commentary  »

With Spinraza 'just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

UNXL

Uni-Pixel

$0.80

-0.01 (-1.23%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Options
Uni Pixel with higher call volume »

Uni Pixel with higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

10:30
04/25/17
04/25
10:30
04/25/17
10:30
General news
The 5.8% March U.S. new home sales surge »

The 5.8% March U.S. new…

EAT

Brinker

$43.93

-1.53 (-3.37%)

10:29
04/25/17
04/25
10:29
04/25/17
10:29
Hot Stocks
Brinker says 'comfortable' with guidance provided for FY17 »

Management said on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

JBLU

JetBlue

$21.75

0.22 (1.02%)

10:28
04/25/17
04/25
10:28
04/25/17
10:28
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on JetBlue, Embraer »

JetBlue says timing…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

QQQ

PowerShares QQQ Trust

$134.16

1.6 (1.21%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Technical Analysis
PowerShares QQQ Trust hits fresh 52-week highs »

The breakout that began…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

C

Citi

$60.29

0.85 (1.43%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Citi confirms receipt of CMA license in Saudi Arabia »

The Saudi Arabian Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

  • 25

    Jul

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
JetBlue aiming for CASM ex-fuel flat to up 1% for 2018-2020 »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BBRY

BlackBerry

$9.29

0.21 (2.31%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$81.41

-2.01 (-2.41%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Eli Lilly says hasn't contemplated scenario to not pursue baricitinib in RA »

On Eli Lilly's Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

10:25
04/25/17
04/25
10:25
04/25/17
10:25
General news
U.S. Richmond Fed manufacturing index dipped to 20 in April »

U.S. Richmond Fed…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.